These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 24566314)
1. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract. Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314 [TBL] [Abstract][Full Text] [Related]
2. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240 [TBL] [Abstract][Full Text] [Related]
3. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866 [TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385 [TBL] [Abstract][Full Text] [Related]
5. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588 [TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Kawasaki K; Fujii M; Sato T Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641 [TBL] [Abstract][Full Text] [Related]
7. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Zanini S; Renzi S; Giovinazzo F; Bermano G Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317 [TBL] [Abstract][Full Text] [Related]
9. Sensitivity and Specificity of the NETest: A Validation Study. Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. Stevenson R; Libutti SK; Saif MW JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561 [TBL] [Abstract][Full Text] [Related]
11. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111 [TBL] [Abstract][Full Text] [Related]
12. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs. Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260 [TBL] [Abstract][Full Text] [Related]
13. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors. Chen P; Wang Q; Xie J; Kwok HF Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326 [TBL] [Abstract][Full Text] [Related]
15. A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins. Palermo A; Capoluongo E; Del Toro R; Manfrini S; Pozzilli P; Maggi D; Defeudis G; Pantano F; Coppola R; Di Matteo FM; Raffaelli M; Concolino P; Falchetti A Hormones (Athens); 2018 Sep; 17(3):427-435. PubMed ID: 30083881 [TBL] [Abstract][Full Text] [Related]
16. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors. Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964 [TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757 [TBL] [Abstract][Full Text] [Related]
18. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704 [TBL] [Abstract][Full Text] [Related]
19. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors. How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]